Investor Overview

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and our diverse stakeholders.

We supply medicines to more than 150 countries and have 71 established business offices in more than 50 countries. We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets..

FAST FACTS

OUR INVESTMENT CASE

Leveraging our strengths and capabilities to deliver long-term shareholder value, while living the Aspen values.

Please click on a title below left for more information.

Responsible corporate citizen and a trusted partner Strategically relevant manufacturing capital Global footprint with a focus on emerging markets Diverse, branded product portfolio Committed management team, strongly aligned with shareholders' interests

Responsible corporate citizen and a trusted partner

We are committed to effective and robust corporate governance making us a trusted partner. We remain committed to continuously improving our reporting, transparency and disclosure.
We are a signatory to the United Nations Global Compact ("UN Global Compact") Initiative.
Aspen is a constituent of the FTSE/JSE Responsible Investment Top 30 Index and the global FTSE4Good Index.

Strategically relevant manufacturing capital

We are a widely accredited and compliant supplier of high quality, affordable medicines.
We have the capabilities to improve and sustain a cost competitive manufacturing base concentrating on high volume products.
Our API and finished dose manufacturing sites present a range of production capabilities and the capital expansion projects underway will provide additional sterile capacity further positioning us as a leading niche specialty pharmaceutical manufacturer.
Our supply chain is overseen by a dedicated team striving towards delivery, on-time and in-full for internal and third party customers.

Global footprint with a focus on emerging markets

With a strong foundation in the South African market, we now have 71 established business offices, weighted towards emerging markets.
Operating in the highly regulated pharmaceutical sector, our geographic footprint provides diversification of our risk exposure.
Our regional sales teams are weighted towards emerging markets, positioning us to benefit from the growth demographics in these territories.

Diverse, branded product portfolio

Committed management team, strongly aligned with shareholders' interests

Group revenue contribution
by segment (R'million)

Commercial Pharmaceuticals contribution:
Emerging and developed markets (R'million)

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

2020 Annual Results Presentation For the year ended 30 June 2020
• PDF 1MB

CAPITAL
DISTRIBUTIONS

All capital distributions to date

SHAREHOLDER
STATISTICS

Analysis of shareholders at 30 June 2019

CORPORATE INFORMATION

All corporate information and contact details

CONTACT DETAILS

Luresha Chetty
+27 31 580 8637
+27 83 260 5889
InvestorRelations@aspenpharma.com

REGISTER FOR ALERTS

WEBCASTS

Click here to view our
Investor Day webcast of
11 December 2020

Click here to view a recording of
Aspen’s results presentation for the
year ended 30 June 2020.

INVESTOR CALENDAR

11
March 2021 2021 Interim Results on SENS

12
March 2021 J.P. Morgan South Africa Healthcare Forum - 2021 Interim Results presentation

09
September 2021 2021 Year End Results on SENS

10
September 2021 2021 Year End Results presentation